MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Surmodics Accounts Receivables 2011-2026 | SRDX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.3 M | 10.8 M | 10.5 M | 9.17 M | 7.68 M | 8.99 M | 8.88 M | 7.21 M | 6.87 M | 7.48 M | 4.75 M | 5.33 M | 5.07 M | 7.69 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 M | 4.75 M | 8.12 M |
Quarterly Accounts Receivables Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.2 M | 11.6 M | 12.6 M | 13.3 M | 13.4 M | 12.3 M | 12.9 M | 10.8 M | 11.8 M | 12.1 M | 10.1 M | 10.5 M | - | 11 M | 8.01 M | 9.17 M | 8.6 M | 9.17 M | 8.06 M | 7.68 M | 7.68 M | 7.68 M | 7.68 M | 8.99 M | 8.99 M | 8.99 M | 9.76 M | 8.88 M | 8.88 M | 8.88 M | 6.7 M | 7.21 M | 7.21 M | 7.21 M | 6.5 M | 6.87 M | 6.87 M | 6.87 M | 5.52 M | 7.48 M | 7.48 M | 7.48 M | 4.44 M | 4.75 M | 4.75 M | 4.75 M | 5.11 M | 5.33 M | 5.33 M | 5.33 M | 4.42 M | 5.07 M | 5.07 M | 5.07 M | 4.77 M | 4.38 M | 4.38 M | 4.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.4 M | 4.38 M | 7.95 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.12 | -0.88 % | $ 1.42 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 27.63 | -4.06 % | $ 297 M |  China |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 209.19 | - | $ 149 B | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 11.26 | - | $ 319 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 23.09 | 0.35 % | $ 698 M | USA |
 |
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 209.54 | - | $ 23.3 B | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 29.94 | 3.46 % | $ 832 M | USA |
 |
CareDx, Inc
CDNA
|
51.1 M | $ 19.25 | 2.45 % | $ 1.03 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
1.22 B | $ 73.09 | -0.23 % | $ 28.5 B | USA |
 |
Interpace Biosciences
IDXG
|
8.54 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | $ 103.45 | 0.06 % | $ 19.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 287.13 | 0.64 % | $ 23.9 B | USA |
 |
Guardant Health
GH
|
138 M | $ 95.4 | 1.04 % | $ 12 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
709 M | $ 166.06 | - | $ 8.23 B | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.43 | 1.14 % | $ 410 M | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 104.09 | -0.54 % | $ 8.59 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
6.85 K | $ 3.86 | 2.93 % | $ 2.07 M | USA |
 |
IDEXX Laboratories
IDXX
|
552 M | $ 649.23 | 4.19 % | $ 52.2 B | USA |
 |
Illumina
ILMN
|
735 M | $ 122.9 | 1.96 % | $ 19.5 B | USA |
 |
Natera
NTRA
|
244 M | $ 209.53 | 0.09 % | $ 20.6 B | USA |
 |
IQVIA Holdings
IQV
|
3.4 B | $ 164.88 | - | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
778 M | $ 1 379.66 | - | $ 28.4 B |  Schweiz |
|
Biodesix
BDSX
|
8.6 M | $ 13.02 | 1.96 % | $ 1.69 B | USA |
 |
Pacific Biosciences of California
PACB
|
36.6 M | $ 1.66 | 5.06 % | $ 421 M | USA |
 |
Lantheus Holdings
LNTH
|
321 M | $ 73.61 | 0.26 % | $ 5.09 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.1 | - | $ 4.82 M | USA |